|
HSP's Operating Income Growth by Quarter and Year
Hospira,'s Operating Income results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
Operating Income Growth Y/Y▼
|
Operating Income Growth Y/Y▼
|
| HSP Operating Income (in millions $) |
FY 2014 |
FY 2013 |
FY 2012 |
FY 2011 |
| IV Quarter |
December |
-
|
53.20
|
30.80
|
-212.30
|
| III Quarter |
September |
227.50
|
29.80
|
-16.50
|
-85.20
|
| II Quarter |
June |
99.50
|
52.20
|
-2.20
|
190.50
|
| I Quarter |
March |
99.60
|
-118.60
|
46.70
|
163.80
|
| FY |
|
426.60
|
16.60
|
58.80
|
56.80
|
| HSP Operating Income third quarter 2014 Y/Y Growth Comment |
HOSPIRA, INC. achieved in the third quarter 2014, above Company average Operating Income surge of 663.42% year on year, to $ 227.50 millions.
Looking into third quarter 2014 results within Major Pharmaceutical Preparations industry 3 other companies have achieved higher Operating Income growth. While Hospira, Inc.' s Operating Income doubling of 663.42% ranks overall at the positon no. 99 in the third quarter 2014.
Explain Operating Income growth
|
| HSP Operating Income ( Y/Y Growth %) |
2014
|
2013 |
2012 |
2011 |
| IV Quarter |
December |
- |
72.73 % |
- |
- |
| III Quarter |
September |
663.42 % |
- |
- |
- |
| II Quarter |
June |
90.61 % |
- |
- |
63.8 % |
| I Quarter |
March |
- |
- |
-71.49 % |
-21.1 % |
| FY |
|
- |
-71.77 % |
3.52 % |
-89.06 % |
HSP Operating Income (Quarter on Quarter Growth %) |
2014
|
2013 |
2012 |
2011 |
| IV Quarter |
December |
- |
78.52 % |
- |
- |
| III Quarter |
September |
128.64 % |
-42.91 % |
- |
- |
| II Quarter |
June |
-0.1 % |
- |
- |
16.3 % |
| I Quarter |
March |
87.22 % |
- |
- |
205.6 % |
| FY (Year on Year) |
|
- |
-71.77 % |
3.52 % |
-89.06 % |
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 1314.46 % |
46.22 % |
-82.4 % |
| (March 31, 2014) |
|
(Dec. 30. 2011) |
|
|
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 1314.46 % |
46.22 % |
-82.4 % |
| (March 31, 2014) |
|
(Dec. 30. 2011) |
|
| Operating Income by Quarter for the Fiscal Years 2011, 2012, 2013, 2014 |
Hospira,'s Q/Q Operating Income Growth
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 370.57 % |
31.82 % |
-80.46 % |
| (June 30, 2007) |
|
|
| HSP's III. Quarter Q/Q Operating Income Comment |
HOSPIRA, INC. achieved in the III. Quarter 2014 above company average sequential Operating Income doubling of 128.64%, to $ 227.50 millions, from $99.50 millions in the second quarter.
HSP is going from strength to strength, not just reporting above average increase, and additionally improving pace, Miguel Carter, Healthcare sector observer allocated in Dallas added.
Within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Operating Income quarter on quarter growth. While Hospira,'s Operating Income growth quarter on quarter, overall rank is 200. |
|
|
|
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 370.57 % |
31.82 % |
-80.46 % |
| (June 30, 2007) |
|
|
| HSP's III. Quarter Q/Q Operating Income Comment |
HOSPIRA, INC. achieved in the III. Quarter 2014 above company average sequential Operating Income doubling of 128.64%, to $ 227.50 millions, from $99.50 millions in the second quarter.
HSP is undergoing a remarkable growth, with reporting better then average growth, but also increasing rate, Miguel Carter, Healthcare sector observer allocated in Dallas said.
Within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Operating Income quarter on quarter growth. While Hospira,'s Operating Income growth quarter on quarter, overall rank is 200. |
|
Hospira,'s 12 Months Operating Income Growth Year on Year
Operating Income TTM Growth |
12 Months Ending
(Sep. 30, 2014) |
12 Months Ending
(June 30. 2014) |
12 Months Ending
(March 31, 2014) |
12 Months Ending
(Dec 31 2013) |
12 Months Ending
(Sep. 30, 2013) |
| Cumulative Operating Income 12 Months Ending |
$ 479.80 |
$ 282.10 |
$ 234.80 |
$ 16.60 |
$ -5.80 |
| Y / Y Operating Income Growth (TTM) |
- |
- |
- |
-71.77 % |
- |
| Year on Year Operating Income Growth Overall
Ranking |
# |
# |
# |
# 1327 |
# |
| Seqeuential Operating Income Change (TTM) |
70.08 % |
20.14 % |
1314.46 % |
- |
- |
| Seq. Operating Income Growth (TTM) Overall
Ranking |
# 99 |
# 139 |
# 139 |
# 0 |
# 0 |
| Cumulative Operating Income growth
Comment |
Hospira, saw improvement in Operating Income growth trend, posting cumulative 12 months Operating Income growth of 663.42% year on year, to $ 480 millions if the fiscal year would have ended in Sep. 30, 2014.
Hospira,'s trailing twelve months Operating Income growth was higher than company's average 0.35% and higher than % growth in June 30. 2014. And, Hospira, realized the fastest Operating Income growth, in Major Pharmaceutical Preparations industry.
But sequential rise was slower at 70.08 % from $282.1 millions recorded in the period from June 30. 2014 to Sep. 30, 2013 Miguel Carter went on.
Yet it was evidence of strength, as the average Q/Q TTM growth stands at 46.22%. In the Sep. 30, 2014 period, Hospira, had cumulative twelve months Operating Income of $ 480 millions compare to Operating Loss of $ -6 millions a year ago.
Not only that Major Pharmaceutical Preparations company has regained the bottom-line, it is already gaining momentum and showing above average Operating Income gain, from the twelve months ending in the quarter before of 70.08 % from $282.1 millions.
HOSPIRA, INC. achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. . |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
1314.46 % |
46.22 % |
-82.4 % |
|
|
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
91.78 % |
0.35 % |
-89.06 % |
| (June 30, 2008) |
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 4 |
| Sector |
# 10 |
| S&P 500 |
# 99 |
|
| Cumulative Operating Income growth
Comment |
Hospira, saw improvement in Operating Income growth trend, posting cumulative 12 months Operating Income growth of 663.42% year on year, to $ 480 millions if the fiscal year would have ended in Sep. 30, 2014.
Hospira,'s trailing twelve months Operating Income growth was higher than company's average 0.35% and higher than % growth in June 30. 2014. And, Hospira, realized the fastest Operating Income growth, in Major Pharmaceutical Preparations industry.
But from twelve months ended June 30. 2014 rise was less at 70.08 % from $282.1 millions reported in twelve months ending a quarter before.
Still it was evidence of strength, while the average sequential Operating Income advancement stands at 46.22%.
The growth was much higher sequentially exhibited at 70.08 % jump from $282.1 millions in twelve months ending a quarter June 30. 2014. In the Sep. 30, 2014 period, Hospira, had cumulative twelve months Operating Income of $ 480 millions compare to Operating Loss of $ -6 millions a year ago.
Even more so, not just that Hospira, has regained the profitability, Hospira, by this time is improving fast and showing better then average Operating Income rise, from the twelve months ending in the quarter June 30. 2014 of 70.08 % from $282.1 millions.
HOSPIRA, INC. achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. . |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
1314.46 % |
46.22 % |
-82.4 % |
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
91.78 % |
0.35 % |
-89.06 % |
| (June 30, 2008) |
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 4 |
| Sector |
# 10 |
| S&P 500 |
# 99 |
|
911.86%